Research reference / four-peptide blend
KLOW peptide blends four research peptides with four very different half-lives
KPV, GHK-Cu, BPC-157 and TB-500 are co-formulated in a single research vial. Each arm has its own mechanism, its own clearance rate, and its own evidence base. This reference covers all four — one component at a time.
In plain English
KLOW peptide is a research blend that puts four separate peptides into one vial: KPV (an anti-inflammatory tripeptide), GHK-Cu (a copper-carrying tripeptide studied for skin and tissue repair), BPC-157 (a 15-amino-acid peptide studied for tendon and gut healing), and TB-500 (a short synthetic fragment based on the actin-binding region of a protein called thymosin beta-4). The most common research-vial composition is 80 mg total — 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV.
Here is what the evidence does and does not say. Each of the four components has its own published research record — mainly in cells and rodents, with limited human data. The blend itself has never been tested in any controlled study. Every claim about the four working together is a mechanistic extrapolation, not a measured result. On top of that, the four peptides clear the body at very different rates (a pharmacokinetic mismatch — more on the klow stack page), so a single dose cannot hold all four at matched exposures at the same time.
What people are researching KLOW for: tissue repair and injury recovery, anti-inflammatory effects, and skin health. What to watch for is on the KLOW effects page.
KLOW
KLOW is a co-formulated, lyophilized research blend — four chemically distinct peptides dissolved together at fixed mass ratios and supplied as a single vial. It is not a single molecule and does not have a single CAS number or molecular weight. The four components do NOT form a new chemical entity; they remain four separate peptides in one solution.
The canonical composition (the most widely listed across independent compounders) is an 80 mg total vial: GHK-Cu 50 mg (the mass-dominant arm at approximately 62.5% of the vial by mass) + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. This is a research-chemical co-formulation. No FDA-approved or pharmacopeial KLOW combination product exists.
None of the four components — individually or as KLOW — is FDA-approved for human use. BPC-157 was placed by FDA in category 2 of the 503A bulk-substances review. TB-500 (the synthetic thymosin beta-4 fragment) is on the WADA Prohibited List (S2, peptide hormones / growth factors) and is banned in sport at all times. Every benefit claim in the literature was established for a single component in isolation, not for this blend.
KLOW peptide blend
The blend rationale is that the four components address different steps of one tissue-repair signaling cascade: KPV suppresses innate-immune transcription (NF-kappaB / MAPK — the molecular switches that turn on inflammation); GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) complex) acts across a broad transcriptomic program toward matrix synthesis, antioxidant defense, and collagen crosslinking, and supplies copper for the enzyme lysyl oxidase (a copper-dependent enzyme that links collagen fibers together); BPC-157 drives the VEGFR2/PI3K/Akt/eNOS angiogenic axis (the pathway that grows new blood vessels into injured tissue); and TB-500's LKKTET motif sequesters G-actin (monomeric, soluble actin — the raw material for cell movement) to accelerate cell migration and wound closure.
In theory these four arms — cytokine suppression, matrix remodeling, vascular supply, and cytoskeletal mobility — are complementary steps of the same cascade. The complication is that no controlled in-vivo or human study has tested the four together. Every synergy claim is a mechanistic extrapolation from the single-component literature [1][3][4][5][6].
KLOW peptide benefits reported in the single-component literature include accelerated tissue repair (BPC-157 research [2]), wound healing and re-epithelialization (thymosin beta-4 / TB-500 research [1]), anti-inflammatory activity in gut mucosa (KPV research [3]), and collagen synthesis and extracellular-matrix remodeling (GHK-Cu research [4][5]).
The pharmacokinetic mismatch — the core honesty of this reference
The most important structural fact about what is klow peptide is a pharmacokinetic one. The four components clear the body at markedly different rates.
BPC-157 has a very short elimination half-life — under approximately 30 minutes in the formal rat/dog pharmacokinetic study [8]. The two tripeptides KPV and GHK-Cu are even smaller molecules and are known to clear rapidly: rat plasma studies show GHK is quickly degraded by peptidases to the dipeptide HK after intravenous dosing [9]. TB-500 (the short Ac-LKKTETQ heptapeptide) behaves differently from full-length native thymosin beta-4, and its systemic pharmacokinetics after subcutaneous injection have not been formally characterized in the same way.
The practical implication: a single co-dissolved 80 mg research vial cannot hold all four components at matched plasma exposures simultaneously. By the time BPC-157 has cleared, the tripeptides have already gone. This built-in mismatch is not a flaw that engineering can easily fix — it is a consequence of putting four peptides with fundamentally different molecular weights and metabolic fates into the same solution. See the full klow stack pharmacokinetics page for the half-life ledger.
KLOW research: what the component literature shows
Component-level findings are what this site documents. In BPC-157 studies, 10 μg/kg improved biomechanical and functional recovery of a fully transected rat Achilles tendon [2]. In thymosin beta-4 (the native protein related to the TB-500 fragment) studies, topical or intraperitoneal thymosin beta-4 increased wound re-epithelialization by 42% at four days and up to 61% at seven days in a rat full-thickness wound model, at doses as low as 10 pg for keratinocyte migration stimulation [1]. In KPV research, nanomolar KPV reduced NF-kappaB and MAPK activation and pro-inflammatory cytokine secretion in intestinal epithelial cells, and oral KPV reduced colitis severity in mice [3]. GHK-Cu stimulated synthesis of collagen and proteoglycans; plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by age 60; and topical GHK-Cu increased collagen production in 70% of treated women [4].
The 2026 Sports Medicine review of peptide therapies for musculoskeletal conditions notes favorable tissue-repair outcomes in animal models but concludes that rigorous human safety data for unapproved compounds including TB-500 are scarce [7]. The first-in-human BPC-157 IV safety pilot administered up to 20 mg to two healthy adults with no observed adverse events [6] — a safety-signal study, not an efficacy trial.
See the full KLOW research section for the complete findings.